
Cardiology
ATTR-CM Symptoms and Hospitalizations Improve With Acoramidis
In a randomized trial, acoramidis preserved patient-reported health status and reduced cardiovascular hospitalizations over 30 months in adults with transthyretin amyloid cardiomyopathy.
Rayan Salih · September 11, 2026 · 7 min
